New drug BBI-825 targets resistant tumors in early trial
NCT ID NCT06299761
First seen Jan 22, 2026 · Last updated May 21, 2026 · Updated 26 times
Summary
This early-phase study tested a new oral drug, BBI-825, in 19 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see how the body handles the drug, both alone and with other targeted therapies. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NEXT Oncology
Irving, Texas, 75039, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Sarcoma Oncology Research Center
Santa Monica, California, 90403, United States
Conditions
Explore the condition pages connected to this study.